Hoth Therapeutics Inc (HOTH)
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Co. is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). In addition, Co. is evaluating a peptide that may be used to slow the transmission of SARS-CoV-2 (HT-002). Co. is also developing a diagnostic device via a mobile device. Co. has interests in assets being developed by third parties including a treatment for patients with lupus.
| Company Name: |
Hoth Therapeutics Inc |
| Website: |
www.hoththerapeutics.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding HOTH: |
1 |
| Total Market Value Held by ETFs: |
$44237 |
| Total Market Capitalization: |
$5.00M |
| % of Market Cap. Held by ETFs: |
0.88% |
|
|
April 25, 2024 • 6:47 PM Eastern
Strong Buy (4.00 out of 4)
90th percentile
|
|
Free HOTH Email Alerts:
